leadf
logo-loader
viewGenprex, Inc.

Genprex names Thomas C. Gallagher as the company’s senior vice president of Intellectual Property and Licensing

Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions

Genprex, Inc. -
Prior to joining Genprex, he served as principal at the Fenagh Group, an IP and licensing consultancy providing guidance to clients in the healthcare sector

Genprex, Inc. (NASDAQ:GNPX) has named Thomas C. Gallagher as the company’s senior vice president of Intellectual Property and Licensing.

The clinical-stage gene therapy company, which is developing potentially life-changing technologies for patients with cancer and diabetes, noted that Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions.

In a statement, Rodney Varner, Genprex's president and chief executive officer commented: "Mr Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the Company’s overall success and value creation. A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline."

READ: Genprex appoints Dr William Gannon as the company’s vice president of Regulatory Affairs

The company noted that Gallagher has more than 20 years of experience as an intellectual property attorney. Prior to joining Genprex, he served as principal at the Fenagh Group, an IP and licensing consultancy providing clients in the healthcare sector guidance on all aspects of patent and trademark portfolio management, intellectual property due diligence, freedom-to-operate analysis and related transactional work.

He has also served as senior vice president of Intellectual Property and Licensing at Kadmon Corporation, LLC, a biopharmaceutical company based in Manhattan. Prior to joining Kadmon, he served as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.), a company focused on stem cell biology. Previously, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing.

While at ImClone, he was responsible for all aspects of intellectual property and led the IP function in multiple due diligence undertakings by major pharmaceutical companies, which resulted in a $2 billion strategic investment, the highest-valued biotech deal ever at the time, and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.

Gallagher is experienced in both patent prosecution and litigation, as well as intellectual property issues relating to business development and licensing matters. His patent litigation experience includes European litigation and opposition proceedings. In addition to a law degree, he holds a Master’s degree in molecular biology. Before becoming an attorney, Gallagher worked as a molecular biologist in France, Spain and the United States. 

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 3.25 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $126.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

3 min read